相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia
Fiorenzo Santoleri et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Outcome measures for adherence data from a medication event monitoring system: A literature review
Linda Hartman et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling
Christel C. L. M. Boons et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients
Christel C. L. M. Boons et al.
ACTA ONCOLOGICA (2019)
Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pree-Post Intervention Multicenter Pilot Study
Avi Leader et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study
Avi Leader et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
A systematic literature review comparing methods for the measurement of patient persistence and adherence
Carol A. Forbes et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines
Christel C. L. M. Boons et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
Alejandro Zulbaran-Rojas et al.
CANCER MEDICINE (2018)
Effects of Food on the Pharmacokinetics of Nilotinib in Chronic Myeloid Leukemia: Enabling Significant Dose Reduction and Relief of Treatment Burden: The NIFOStudy
Christel C. Boons et al.
BLOOD (2018)
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Ami B. Patel et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries
Jan Geissler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling
Christel C. L. M. Boons et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2017)
Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO
Reina Haque et al.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2017)
Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency
Dominick Latremouille-Viau et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response
Fiorenzo Santoleri et al.
ACTA HAEMATOLOGICA (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence
Mohamed El Alili et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients
Alix E. Hall et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
Massimo Breccia et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia
Aaron N. Winn et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival A Systematic Review and Meta-analysis
Jonathan Douxfils et al.
JAMA ONCOLOGY (2016)
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
N. Ader I. Al-Dewik et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2016)
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
Masatomo Miura
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
Susanne Saussele et al.
BLOOD (2015)
Medication Adherence Measures: An Overview
Wai Yin Lam et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs
Melea A. Ward et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia
Kristin R. Anderson et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Interventions for adherence with oral chemotherapy in hematological malignancies: A systematic review
Jan Kavookjian et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2015)
Adherence and patients' experiences with the use of oral anticancer agents
Lonneke Timmers et al.
ACTA ONCOLOGICA (2014)
Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia
Christel C. L. M. Boons et al.
BMC CANCER (2014)
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia
Fabio Efficace et al.
HAEMATOLOGICA (2014)
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Lucien Noens et al.
HAEMATOLOGICA (2014)
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment
Digisha Trivedi et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2014)
Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort
Maria H. de Almeida et al.
ACTA HAEMATOLOGICA (2013)
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
Loretta A. Williams et al.
BLOOD (2013)
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
Francis J. Giles et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
F. Efficace et al.
LEUKEMIA (2013)
Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
Fiorenzo Santoleri et al.
PLOS ONE (2013)
Understanding Patients' Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework
Rob Horne et al.
PLOS ONE (2013)
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
Marianne Ulcickas Yood et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Richard A. Larson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia
Prasanth Ganesan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
Amr R. Ibrahim et al.
BLOOD (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Factor structure and longitudinal invariance of the Medical Adherence Report Scale-Asthma
Pablo A. Mora et al.
PSYCHOLOGY & HEALTH (2011)
Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts
S. V. Kane et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
C. Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia
Eric Q. Wu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma
Jessica L. Cohen et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Ethan Basch et al.
LANCET ONCOLOGY (2006)
The Brief Illness Perception Questionnaire
Elizabeth Broadbent et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH (2006)
Intentional and unintentional nonadherence: A study of decision making
AL Wroe
JOURNAL OF BEHAVIORAL MEDICINE (2002)
The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research
R Horne et al.
QUALITY IN HEALTH CARE (2001)
分享论文
